Relationship between aggregation of therapeutic proteins and agitation parameters: Acceleration and frequency

J Pharm Sci. 2023 Feb;112(2):492-505. doi: 10.1016/j.xphs.2022.09.022. Epub 2022 Sep 24.

Abstract

An increase in protein aggregates during transportation should be suppressed in therapeutic protein products because the aggregates have a potential risk of immunogenicity. In this study, three protein solutions in vials were exposed to tri-axial vibration with various combinations of frequency and acceleration using a transportation test system to investigate the relationship between low g-force stresses and protein aggregate generation. The number concentration of micron aggregates detected by flow imaging analysis increased markedly when the acceleration and frequency of agitation were within a specific range, in other words, above a threshold. This threshold was common among the three protein solutions. The suppression of micron aggregate formation by adding a surfactant suggested that agitation above the threshold increased micron aggregates mainly via interface-mediated routes. Notably, agitation, including agitation below the threshold, accelerated spontaneous oligomerization (nanometer aggregate generation) of proteins in bulk solution even in the presence of the surfactant. Studies of stability against mechanical stresses (e.g., a random vibration test to simulate actual shipment, with a time-compressed setting by increasing acceleration) need to be performed and discussed with careful consideration of the threshold for generating micron aggregates.

Keywords: Biopharmaceutical characterization; Microparticles; Monoclonal antibody; Particle size; Physical stability; Protein aggregation; Protein formulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal* / metabolism
  • Protein Aggregates
  • Stress, Mechanical
  • Surface-Active Agents*

Substances

  • Antibodies, Monoclonal
  • Surface-Active Agents
  • Protein Aggregates